308 related articles for article (PubMed ID: 30187345)
41. Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia.
Yamasaki T; Iwashima Y; Jesmin S; Ohta Y; Kusunoki H; Hayashi S; Horio T; Kawano Y
PLoS One; 2014; 9(2):e89057. PubMed ID: 24586502
[TBL] [Abstract][Full Text] [Related]
42. Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas.
Zhou X; Wu L; Chen Y; Xiao H; Huang X; Li Y; Xiao H; Cao X
J Diabetes Investig; 2021 Jul; 12(7):1278-1286. PubMed ID: 33289308
[TBL] [Abstract][Full Text] [Related]
43. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.
Poolsup N; Suksomboon N; Wongyaowarat K; Rungkanchananon B; Niyomrat P; Kongsuwan S
J Clin Pharm Ther; 2012 Apr; 37(2):166-72. PubMed ID: 21585411
[TBL] [Abstract][Full Text] [Related]
44. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.
Eriksson M; Budinski D; Hounslow N
Adv Ther; 2011 Sep; 28(9):811-23. PubMed ID: 21874538
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
46. A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Sadeq A; Elnour AA; Farah FH; Ramadan A; Baraka MA; Don J; Amoodi AA; Sam KG; Mazrouei NA; Alkaabi M
Curr Rev Clin Exp Pharmacol; 2023; 18(2):120-147. PubMed ID: 35642121
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
48. Pitavastatin - from clinical trials to clinical practice.
Masana L
Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
[TBL] [Abstract][Full Text] [Related]
49. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
50. Statin diabetogenicity: guidance for clinicians.
Ray K
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S3. PubMed ID: 23819776
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Messerli FH; Bakris GL; Ferrera D; Houston MC; Petrella RJ; Flack JM; Sun W; Lee E; Neutel JM;
J Clin Hypertens (Greenwich); 2006 Aug; 8(8):571-81; quiz 582-3. PubMed ID: 16896273
[TBL] [Abstract][Full Text] [Related]
52. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
[TBL] [Abstract][Full Text] [Related]
53. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
Hari P; Khandelwal P; Satpathy A; Hari S; Thergaonkar R; Lakshmy R; Sinha A; Bagga A
Pediatr Nephrol; 2018 Dec; 33(12):2299-2309. PubMed ID: 30091061
[TBL] [Abstract][Full Text] [Related]
54. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Ogata N; Fujimori S; Oka Y; Kaneko K
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
[TBL] [Abstract][Full Text] [Related]
55. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
[TBL] [Abstract][Full Text] [Related]
56. Pitavastatin and HDL: Effects on plasma levels and function(s).
Pirillo A; Catapano AL
Atheroscler Suppl; 2017 Jul; 27():e1-e9. PubMed ID: 28716185
[TBL] [Abstract][Full Text] [Related]
57. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
[TBL] [Abstract][Full Text] [Related]
58. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
Arnaboldi L; Corsini A
Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
[TBL] [Abstract][Full Text] [Related]
59. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
60. Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.
Zhang X; Xing L; Jia X; Pang X; Xiang Q; Zhao X; Ma L; Liu Z; Hu K; Wang Z; Cui Y
Cardiovasc Ther; 2020; 2020():3987065. PubMed ID: 32411300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
